There is mounting evidence for the use of ketamine/esketamine in the treatment of depression. This paper examines how comorbid borderline personality disorder, or traits, may impact the efficacy of ketamine/esketamine in the treatment of depressive disorders.
Aims:
To evaluate the efficacy of ketamine/esketamine in the treatment of depression where there are comorbid borderline personality disorder/traits.
Method:
MEDLINE, Embase, APA PsycInfo, CINAHL and Scopus databases were searched for English language journal articles focusing on the use of ketamine/esketamine to treat depression in patients with comorbid borderline personality disorder/traits. Analysis included study design and intervention, efficacy statistics relating to the treatment of depression, as well as study limitations.
Results:
Nine studies (n = 281) were included. Ultimately, patients with depression and comorbid borderline personality disorder/traits were equally likely to respond to ketamine/esketamine as those with depression but without borderline personality disorder/traits.
Conclusion:
This is the first systematic review to assess the effectiveness of ketamine/esketamine in this cohort. Our findings suggest that ketamine/esketamine may be useful in improving symptoms of depression, in those with comorbid borderline personality disorder. Limited study data are available; however, given case reports of suicidal ideation and self-harm following treatment cessation, as well as indications of a higher risk of acute dissociation in individuals with borderline personality disorder, clinicians should exercise caution when using ketamine to treat depression in this population. More data are required including a larger randomised control trial to assess the efficacy and side effects of ketamine/esketamine in this study population. Clinicians should, where available and appropriate, consider offering ketamine/esketamine to patients in this cohort.
AbdallahCGAverillLACollinsKA, et al. (2017) Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacology42(6): 1210–1219. http://doi.org/10.1038/npp.2016.186
2.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders: DSM-5™, 5th Edition. Arlington, VA: American Psychiatric Publishing.
3.
AnandAMathewSJSanacoraG, et al (2023) Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine388: 2315–2325.
4.
BarkerTHStoneJCSearsK, et al (2023) The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evidence Synthesis21: 494–506.
5.
BenedettiF (2020) Placebo Effects. Oxford: Oxford University Press.
6.
BroadbearJRaoS (2015) Psychotherapy for borderline personality disorder reduces the need for prescription medication. European Psychiatry30: 1.
7.
BroadbearJHDwyerJBugejaLRaoS (2020) Coroners investigations of suicide in Australia: The hidden toll of border line personality disorder. Journal of Psychiatric Research129: 241–249.
8.
ChenKSDwivediYSheltonRC (2022) The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder. Journal of Affective Disorders315: 13–16.
9.
Choi-KainLWSahinZTraynorJ (2022) Borderline personality disorder: Updates in a postpandemic world. Focus (American Psychiatric Publishing)20: 337–352.
10.
DanayanKChisamoreNRodriguesNB, et al (2023) Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Research323: 115–133.
11.
de FilippisRDe FazioP (2023) Esketamine nasal spray in severe bipolar depression with borderline personality disorder and history of multiple substance abuse: A case report. Bipolar Disorders25: 524–526.
12.
FerreaSPetridesGEhrt-SchäferY, et al (2024) Outcomes of electroconvulsive therapy in patients with depressive symptoms with versus without comorbid personality disorders/traits: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica149: 18–32.
13.
FinebergSKChoiEYShapiro-ThompsonR, et al (2023) A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology48: 991–999.
14.
FyerMRFrancesAJSullivanT, et al (1988) Suicide attempts in patients with borderline personality disorder. The American Journal of Psychiatry145: 737–739.
15.
Gałuszko-WęgielnikMJakuszkowiak-WojtenKWilkowskaA, et al (2023) Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity. The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry24: 849–853.
16.
GrunebaumMFGalfalvyHCChooT-H, et al (2018) Ketamine for rapid reduction of suicidal thoughts in major depression: A midazolam-controlled randomized clinical trial. American Journal of Psychiatry175: 327–335.
17.
IliakisEAIlaganGSChoi-KainLW (2021) Dropout rates from psychotherapy trials for borderline personality disorder: A meta-analysis. Personality Disorders12: 193–206.
18.
JacksonHJBurgessPM (2000) Personality disorders in the community: A report from the Australian National Survey of Mental Health and Wellbeing. Social Psychiatry and Psychiatric Epidemiology35: 531–538.
19.
JuurlinkTTTen HaveMLamersF, et al (2018) Borderline personality symptoms and work performance: A population-based survey. BMC Psychiatry18: 202.
20.
KellyTMSoloffPHLynchKG, et al (2000) Recent life events, social adjustment, and suicide attempts in patients with major depression and borderline personality disorder. Journal of Personality Disorders14: 316–326.
21.
LeichsenringFHeimNLewekeF, et al (2023) Borderline personality disorder: A review. JAMA329: 670–679.
22.
LiebKVöllmBRückerG, et al (2010) Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. The British Journal of Psychiatry: The Journal of Mental Science196: 4–12.
23.
LooCGlozierNBartonD, et al (2023) Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial. The British Journal of Psychiatry223: 533–541.
24.
MoolaSMunnZTufanaruC, et al (2017) Systematic reviews of etiology and risk. In: AromatarisELockwoodCPorrittK, et al. (eds) Joanna Briggs Institute Reviewer’s Manual. Adelaide, SA, Australia:The Joanna Briggs Institute Adelaide, pp. 217–269.
25.
MurroughJWSoleimaniLDeWildeK, et al (2015) Ketamine for rapid reduction of suicidal ideation: A randomized controlled trial. Psychological Medicine45: 3571–3580.
26.
NandanNKSoniPKParsaikA, et al (2022) ‘Esketamine’ in borderline personality disorder: A look beyond suicidality. Cureus14: e24632.
27.
National Institute for Health Care Excellence (NICE) (2009) Borderline personality disorder: Recognition and management. CG78. Available at: www.nice.org.uk/guidance/cg78 (accessed 2 July 2024).
28.
NikolinSRodgersASchwaabA, et al (2023) Ketamine for the treatment of major depression: A systematic review and meta-analysis. Eclinicalmedicine62: 102127.
29.
PageMJMcKenzieJEBossuytPM, et al (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ372: n71.
30.
PurohithANChatorikarSANagarajAKM, et al (2021) Ketamine for non-suicidal self-harm in borderline personality disorder with co-morbid recurrent depression: A case report. Journal of Affective Disorders Reports6: 100280.
RoggHAvramMMüllerF, et al (2023) Ketamine as a treatment option for severe borderline personality disorder: A case report. Journal of Clinical Psychopharmacology43: 64–65.
33.
RunesonBOdebergJPetterssonA, et al (2017) Instruments for the assessment of suicide risk: A systematic review evaluating the certainty of the evidence. PLoS ONE12: e0180292.
34.
RyanEPOquendoMA (2020) Suicide risk assessment and prevention: Challenges and opportunities. Focus (American Psychiatric Publishing)18: 88–99.
35.
SalsmanNLLinehanMM (2012) An investigation of the relationships among negative affect, difficulties in emotion regulation, and features of borderline personality disorder. Journal of Psychopathology and Behavioral Assessment34: 260–267.
36.
ShortBFongJGalvezV, et al (2018) Side-effects associated with ketamine use in depression: A systematic review. The Lancet: Psychiatry5: 65–78.
37.
TomkoRLTrullTJWoodPK, et al (2014) Characteristics of borderline personality disorder in a community sample: Comorbidity, treatment utilization, and general functioning. Journal of Personality Disorders28: 734–750.
38.
VanicekTUnterholznerJLanzenbergerR, et al (2022) Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry23: 715–718.
39.
WilkinsonSTFarmerCBallardED, et al (2019) Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology44: 1233–1238.
40.
YenSPetersJRNisharS, et al (2021) Association of borderline personality disorder criteria with suicide attempts: Findings from the Collaborative longitudinal study of personality disorders over 10 years of follow-up. JAMA Psychiatry78: 187–194.
41.
ZanariniMCFrankenburgFRHennenJ, et al (2004) Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. The American Journal of Psychiatry161: 2108–2114.
42.
ZimmermanMMorganTA (2013) Problematic boundaries in the diagnosis of bipolar disorder: The interface with borderline personality disorder. Current Psychiatry Reports15: 422–410.
